Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Quince Therapeutics, Inc.QNCX · Entity 7403 | Director · CEO and CMO | January 23, 2026 | January 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Quince Therapeutics, Inc.
Report date January 23, 2026 · Filed January 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.08 · Expires 2036-01-23 | Direct | 1,000,000 |
Reported balance
After 2026-01-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-23 · Grant · Acquired 1,000,000 · Balance 1,000,000 F1: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting with 1/48th vesting on the date of grant and the remaining options vesting on the 1st day of each subsequent month, such that the total number of shares shall be fully vested on December 1, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting with 1/48th vesting on the date of grant and the remaining options vesting on the 1st day of each subsequent month, such that the total number of shares shall be fully vested on December 1, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2026 Filed Jan 23, 2026 20:25 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,000,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000912282-26-000121 · form4.xml · derivative · entry 1 Thye Dirk · CIK 0001638945 · Director · CEO and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Shares · 1,000,000 shares Expires 2036-01-23 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting with 1/48th vesting on the date of grant and the remaining options vesting on the 1st day of each subsequent month, such that the total number of shares shall be fully vested on December 1, 2029. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 17:07 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GiftCommon Shares | 739,885 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-001407 · form4.xml · nonDerivative · entry 2 Thye Dirk · CIK 0001638945 · Director · CEO and CMO 10b5-1 filing: No plan indicated Ownership: Indirect · Thye Trust Disclosed balance after: 739,885 Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 17:07 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GiftCommon Shares | 739,885 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-001407 · form4.xml · nonDerivative · entry 1 Thye Dirk · CIK 0001638945 · Director · CEO and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,000 Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 08:43 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantWarrants · Derivative | 150,944 | $0.13 Strike: $1.20 | $18,868.00 |
DisclosureSEC source: 0000912282-25-000695 · form4.xml · derivative · entry 2 Thye Dirk · CIK 0001638945 · Director · CEO and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,944 Underlying: Common Shares · 150,944 shares Expires 2030-06-18 Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 08:43 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantCommon Shares | 150,944 | $1.20 | $181,132.80 |
DisclosureSEC source: 0000912282-25-000695 · form4.xml · nonDerivative · entry 1 Thye Dirk · CIK 0001638945 · Director · CEO and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 994,885 Read SEC document |
| January 28, 2025 Filed Feb 11, 2025 17:44 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (right to buy) · Derivative | 1,200,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001415889-25-003618 · form4-02112025_100234.xml · derivative · entry 1 Thye Dirk · CIK 0001638945 · Director · CEO AND CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,200,000 Underlying: Common Stock · 1,200,000 shares Expires 2035-01-27 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2025, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date. Read SEC document |
| August 30, 2024 Filed Sep 3, 2024 17:38 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | PurchaseCommon Stock | 77,000 | $0.70 | $53,900.00 |
DisclosureSEC source: 0001415889-24-022702 · form4-09032024_090940.xml · nonDerivative · entry 2 Thye Dirk · CIK 0001638945 · Director · CEO AND CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 843,941 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.67 to $0.72, inclusive. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 17:38 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | PurchaseCommon Stock | 77,500 | $0.69 | $53,475.00 |
DisclosureSEC source: 0001415889-24-022702 · form4-09032024_090940.xml · nonDerivative · entry 1 Thye Dirk · CIK 0001638945 · Director · CEO AND CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 766,941 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.66 to $0.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 17:50 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (right to buy) · Derivative | 1,500,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001415889-24-002378 · form4-02022024_100215.xml · derivative · entry 1 Thye Dirk · CIK 0001638945 · Director · CEO AND CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 1,500,000 shares Expires 2034-01-31 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2024, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date. Read SEC document |
| January 16, 2024 Filed Jan 17, 2024 16:48 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 149,999 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001415889-24-001313 · form4-01172024_090120.xml · derivative · entry 4 Thye Dirk · CIK 0001638945 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,001 Underlying: Common Stock · 149,999 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date. Read SEC document |
| January 16, 2024 Filed Jan 17, 2024 16:48 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 90,531 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001415889-24-001313 · form4-01172024_090120.xml · derivative · entry 3 Thye Dirk · CIK 0001638945 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,860 Underlying: Common Stock · 90,531 shares Expires 2022-03-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years. Read SEC document |
| January 16, 2024 Filed Jan 17, 2024 16:48 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | Exercise / conversionCommon Stock | 149,999 | $0.94 | $140,999.06 |
DisclosureSEC source: 0001415889-24-001313 · form4-01172024_090120.xml · nonDerivative · entry 2 Thye Dirk · CIK 0001638945 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 689,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2024 Filed Jan 17, 2024 16:48 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | Exercise / conversionCommon Stock | 90,531 | $0.55 | $49,792.05 |
DisclosureSEC source: 0001415889-24-001313 · form4-01172024_090120.xml · nonDerivative · entry 1 Thye Dirk · CIK 0001638945 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 539,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 16:15 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | PurchaseCommon Stock | 88,000 | $1.26 | $110,880.00 |
DisclosureSEC source: 0001209191-23-045432 · doc4.xml · nonDerivative · entry 1 Thye Dirk · CIK 0001638945 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 448,911 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.23 to $1.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 08, 2023 Filed Aug 9, 2023 18:23 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | PurchaseCommon Stock | 80,000 | $1.24 | $99,200.00 |
DisclosureSEC source: 0001209191-23-045235 · doc4.xml · nonDerivative · entry 1 Thye Dirk · CIK 0001638945 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 360,911 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.22 to $1.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 18:37 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001209191-23-006402 · doc4.xml · derivative · entry 1 Thye Dirk · CIK 0001638945 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date. Read SEC document |
| May 23, 2022 Filed May 23, 2022 20:29 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantEmployee Stock Option (right to buy) · Derivative | 1,979,650 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001209191-22-031515 · doc4.xml · derivative · entry 3 Thye Dirk · CIK 0001638945 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,979,650 Underlying: Common Stock · 1,979,650 shares Expires 2032-05-22 F2 · derivative.exercise_date: The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years. Read SEC document |
| May 19, 2022 Filed May 23, 2022 20:29 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantEmployee Stock Option (right to buy) · Derivative | 206,391 | Not disclosed Strike: $0.55 | Not disclosed |
DisclosureSEC source: 0001209191-22-031515 · doc4.xml · derivative · entry 2 Thye Dirk · CIK 0001638945 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,391 Underlying: Common Stock · 206,391 shares Expires 2022-03-27 F3 · price: Received in the Merger in exchange for an employee stock option to acquire 2,266,500 shares of Novosteo common stock for $0.05 per share. F2 · derivative.exercise_date: The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years. Read SEC document |
| May 19, 2022 Filed May 23, 2022 20:29 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantCommon Stock | 64,589 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-031515 · doc4.xml · nonDerivative · entry 1 Thye Dirk · CIK 0001638945 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,589 F1 · price: On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer. Read SEC document |
| May 19, 2022 Filed May 27, 2022 17:35 UTC Amendment | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantCommon Stock | 216,322 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032675 · doc4a.xml · nonDerivative · entry 1 Thye Dirk · CIK 0001638945 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,911 F1 · shares: The shares vest monthly, subject to continued service. F2 · price: On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.